← Back to all trials
Not Yet Recruiting
NCT05739903
Phamacokinetics and Safety Profiles of DA-1229_01 5/1000mg in Healthy Subjects at Fasting State
Conditions: Healthy
Sex: All
Ages: 19 Years – N/A
Healthy volunteers: 1
Phase: PHASE1
Enrollment: 40
Sponsor: Dong-A ST Co., Ltd.
Location: Korea, Republic of
Summary
This Phase I clinical study is to evaluate the safety/tolerability and pharmacokinetics of DA-1229_01 (5/1000 mg x1 tablets) at fasting state.
Eligibility Criteria
Inclusion Criteria:Healthy VolunteersBMI between 18 and 30 kg/m2Body weight : Male≥50kg, Female≥45kgExclusion Criteria:Allergy or Drug hypersensitivityClinically significant Medical History
Source: ClinicalTrials.gov (NCT05739903). StuddyBuddy aggregates publicly available trial information.
